

Plasma Protein Products Transition

August 2018

NEWS

Transition support

Canadian Blood Services is committed to continued updates on the plasma protein product transition. This includes product ordering and other relevant information via this monthly newsletter. Our goal is to broadly communicate the status of product inventories and to provide specific updates with clear direction on required product transitions.

Cuvitru: Shire has received Health Canada approval for extended room temperature storage from 24 months from date of manufacture. Please refer to the updated product monograph.

Eloctate and Alprolix : Demand for these products continues to be higher than expected in some centers. With the exception of those patients who are eligible to continue to use these products, transitioning patients should be completed by September 2018. Any delay in transitioning may impact the availability of these products.

Named-patient management (Eloctate and Alprolix)

As previously communicated, a process for ordering Eloctate and Alprolix on a named-patient basis is being finalized. A Customer Letter will be issued in the near future to describe this new ordering process in more detail. Product volume information provided to Canadian Blood Services to date to support pediatric patients population, ITI and those in their pre-exposure treatments has been very helpful with supply planning.



UPDATES

Ordering products

Please submit large orders covering several weeks of product at least one week before the needed delivery date. This lead time will allow sufficient time to ensure proper levels of product are available where and when they are needed. Product order forms can be found at www.blood.ca.

Phase-out timelines for some products continue to be adjusted as transitions take place. Please see pages 2 for updated information.

Gammagard Liquid 30g and Gamunex: Demand for these brands in particular is higher than the targeted percentage share splits in some centers. It is important to ensure we meet our contractual requirements so substitutions may be required until percentage share targets have been met. As described in Customer Letter 2018-15 Annual IG Availability, the 2018-19 target percentage share for Gammagard Liquid is 41% and for Gamunex is 18%. The charts on pages 4 and 5 demonstrate that we will not meet these targets based on the current forecast .

Note: Please refer to product monographs for infusion rates for new or transitioning patients. Mild patient AEs have been reported in cases where (initial) infusion rates have not been followed.

Please refer to Product Tracking charts on pages 4 and 5.

Customer letters can be viewed at blood.ca in the Hospitals section.

CONTACT US

Day-to-day operations and additional information on products and inventory:

Contact your local Canadian Blood Services site or Jennifer Davis, plasma protein products and services team, jennifert.davis@blood.ca.

New products and product support:

Hizentra CARE	1-888-490-4105		
Shire	1-888-999-0287	OnePath	1-844-691-7284
Novo Nordisk	1-800-465-4334		
Other product enquiries : Contact csr@blood.ca			

August 2018

<i>Product category</i>	Product	Size	Target month phase-out
<i>Intravenous immune globulin</i>	Panzyga	2.5 g, 5 g	No longer available
		10 g	July 2018
		20 g	September 2018
		30 g	February 2019
	Privigen	10 g	January 2019
		40 g	July 2018
<i>Subcutaneous immune globulin</i>	Hizentra	1 g pre-filled syringes	October 2018
		2 g pre-filled syringes	September 2018
		4 g	August 2018
		10 g	November 2018
<i>Albumin</i>	Plasbumin (Grifols)	5% 250 mL	December 2018
	Albumin (Grifols)	5% 250 mL	December 2018
<i>Long-acting recombinant factor VIII (Note 1)</i>	Eloctate*	250 IU	No longer available
		500 IU, 750 IU, 1,000 IU, 1,500 IU, 2,000 IU, 3,000 IU	Transition patients by September 2018
<i>Long-acting recombinant factor IX (Note 1)</i>	Alprolix*	500 IU, 1,000 IU, 2,000 IU, 3,000 IU	Transition patients by September 2018

***Note 1:** Quantities of product to remain available on a named- patient basis with access to the specific categories agreed to. Transitions to other products for all other patients should be scheduled for completion by September 2018

SUMMARY OF PRODUCT CHANGES

Red (underlined): not continuing

Blue (**bold**): new

August 2018





Previous product mix		Future product mix	
Product	Size	Product	Size
Intravenous immune globulin		Intravenous immune globulin	
Gamunex, Grifols	2.5 g, 5 g, 10 g, 20 g	Gamunex, Grifols	2.5 g, 5 g, 10 g, 20 g
IVIgNex, Grifols	20 g	IVIgNex, Grifols	20 g
Privigen, CSL Behring	2.5 g, 5 g, <u>10 g</u> , 20 g, <u>40 g</u>	Privigen, CSL Behring	2.5 g, 5 g, 20 g
Gammagard Liquid, Shire	5 g, 10 g	Gammagard Liquid, Shire	2.5 g , 5 g, 10 g, 20 g , 30 g
<u>Panzyga, Octapharma</u>	<u>2.5 g, 5 g, 10 g, 20 g, 30 g</u>		
Subcutaneous immune globulin		Subcutaneous immune globulin	
<u>Hizentra, CSL Behring</u>	<u>1 g, 2 g, 4 g, 10 g</u>	Cuvitru, Shire	1 g, 2 g, 4 g, 8 g
Albumin		Albumin	
Plasbumin, Grifols	5% 50 mL, <u>5% 250 mL</u> , <u>25% 100 mL</u>	Plasbumin, Grifols	5% 50 mL
Albumin, Grifols	25% 100 mL	Albumin, Grifols	25% 100 mL
Alburex, CSL Behring	5% 250 mL, 5% 500 mL, 25% 50 mL, 25% 100 mL	Alburex, CSL Behring	5% 250 mL, 5% 500 mL, 25% 50 mL, 25% 100 mL
Recombinant factor VIII		Recombinant factor VIII	
Xyntha, Pfizer	250 IU, 500 IU, 1,000 IU, 2,000 IU, 3,000 IU	Xyntha, Pfizer	250 IU, 500 IU, 1,000 IU, 2,000 IU, 3,000 IU
Nuwiq, Octapharma	250 IU, 500 IU, 1,000 IU, 2,000 IU	Nuwiq, Octapharma	250 IU, 500 IU, 1,000 IU, 2,000 IU, 3,000 IU, 4,000 IU
Kovaltry, Bayer	250 IU, 500 IU, 1,000 IU, 2,000 IU, 3,000 IU	Kovaltry, Bayer	250 IU, 500 IU, 1,000 IU, 2,000 IU, 3,000 IU
<u>Eloctate, Bioverativ (long-acting)*</u>	<u>250 IU, 500 IU, 750 IU, 1,000 IU</u> , <u>1,500 IU, 2,000 IU, 3,000 IU</u>	Adynovate, Shire (long-acting)	250 IU, 500 IU, 1,000 IU, 2,000 IU
Recombinant factor IX		Recombinant factor IX	
Benefix, Pfizer	500 IU, 1,000 IU, 2,000 IU, 3,000 IU	Benefix, Pfizer	500 IU, 1,000 IU, 2,000 IU, 3,000 IU
<u>Alprolix, Bioverativ (long-acting)*</u>	<u>500 IU, 1,000 IU, 2,000 IU</u> , <u>3,000 IU</u>	Rebinyn, Novo Nordisk (long-acting)	500 IU, 1,000 IU, 2,000 IU

*NOTE: Quantities of product to remain available on a named-patient basis with access to the specific categories agreed with the exception of Eloctate 250

Product Tracking - Issues

August 2018

using April forecast as baseline



Product Tracking - Issues

August 2018

